Newsroom | 5051 results

BÂLE, Suisse--(BUSINESS WIRE)--Ascensia Diabetes Care, une société internationale spécialisée dans le traitement du diabète et une filiale de PHC Holdings Corporation (TSE : 6523), a annoncé aujourd’hui la nomination de Peter Bodlund au poste de président-directeur général, à compter du 1er avril 2026. Il succède à Koichiro Sato, qui continuera d’exercer ses fonctions de directeur de l’exploitation et de responsable de l’activité Gestion du diabète de PHC Group. M. Bodlund a occupé divers poste...

BASEL, Schweiz--(BUSINESS WIRE)--Ascensia Diabetes Care, ein weltweit tätiges Unternehmen für Diabetesversorgung und eine Tochtergesellschaft der PHC Holdings Corporation (TSE: 6523), teilte heute mit, dass Peter Bodlund mit Wirkung zum 1. April 2026 zum President und CEO ernannt wurde. Er tritt die Nachfolge von Koichiro Sato an, der seine Funktionen als Chief Operating Officer der PHC Group und Leiter des Geschäftsbereichs Diabetes Management weiterhin ausüben wird. Peter Bodlund war in leite...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. D...

GLASGOW, Scotland & MILWAUKEE--(BUSINESS WIRE)--Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases...

BASEL, Switzerland--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company and subsidiary of PHC Holdings Corporation (TSE: 6523), today announced the appointment of Peter Bodlund as President and Chief Executive Officer, effective April 1, 2026. He succeeds Koichiro Sato, who will continue in his roles as Chief Operating Officer of PHC Group and Head of PHC Group’s Diabetes Management business. Peter has held senior leadership roles across global healthcare and life sciences o...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a...

MADISON, Wis.--(BUSINESS WIRE)--Nearly seven in 10 Americans who have taken a GLP-1 medication say the drug’s cost influenced their decision to start or continue treatment, according to a new nationwide Navitus Health Solutions Pulse Survey released today. “GLP-1 medications offer meaningful health benefits, but this survey highlights trends and concerns related to medication cost and long-term accessibility to these drugs,” said Sharon Faust, Chief Pharmacy Officer at Navitus Health Solutions,...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. “Today’s approval is a watershed moment for Allurion and for obesity care in the United States,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “Our goal is to deliv...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2025 and provided its financial guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial and Strategic Highlights Achieved record quarterly sales: Worldwide sales of $290.4 million United States sales of $210.5 million Worldwide pump shipments of 38,000 United...